← All Connect Biopharma Holdings LTD filings

Connect Biopharma Holdings LTD 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

31 Mar 2026

CNTB

10-K: Connect Biopharma Reports Increased Losses, Advances Rademikibart Trials

Connect Biopharma reported a significant increase in net loss for 2025, while advancing its lead drug candidate, rademikibart, into Phase 2 trials for acute asthma and COPD, and securing a private placement for additional funding.

NASDAQ

31 Mar 2025

CNTB

Connect Biopharma Holdings LTD

10-K: Connect Biopharma Focuses on Asthma and COPD Programs After Simcere Deal

Connect Biopharma is prioritizing rademikibart for asthma and COPD, leveraging a partnership with Simcere in Greater China, according to its recent 10-K filing.